doi: 10.4161/onci.20639.
Interleukin-2 treatment of tumor patients can expand regulatory T cells
Affiliations
- PMID: 23170272
- PMCID: PMC3494638
- DOI: 10.4161/onci.20639
Item in Clipboard
Interleukin-2 treatment of tumor patients can expand regulatory T cells
Oncoimmunology.
.
Abstract
Augmented numbers of regulatory T cells contribute to the overall immunosuppression in tumor patients. Interleukin-2 has been widely used in the clinics in anticancer therapy, yet evidence has accumulated that the major drawback, limiting clinical efficacy, is the expansion of regulatory T cells, which aggravates immunosuppression.
Figures
Figure 1. Interleukin 2 administration results in a preferential expansion of regulatory T (Treg) cells. Administration of interleukin-2 to tumor patients only results in a weak activation and expansion of potentially tumor-counteracting effector T cells, while memory Treg cells in the periphery as well as the naïve thymic Treg-cell pool are consistently expanded.
Similar articles
-
Rapamycin promotes the enrichment of CD4(+)CD25(hi)FoxP3(+) T regulatory cells from naïve CD4(+) T cells of baboon that suppress antiporcine xenogenic response in vitro.Transplant Proc. 2009 Jan-Feb;41(1):418-21. doi: 10.1016/j.transproceed.2008.10.079. Transplant Proc. 2009. PMID: 19249569 Free PMC article.
-
Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.Nephrol Dial Transplant. 2012 Jun;27(6):2576-82. doi: 10.1093/ndt/gfr693. Epub 2011 Dec 13. Nephrol Dial Transplant. 2012. PMID: 22167587
-
Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity.Immunol Rev. 2006 Aug;212:314-29. doi: 10.1111/j.0105-2896.2006.00422.x. Immunol Rev. 2006. PMID: 16903923 Review.
-
IL-15 and cognate antigen successfully expand de novo-induced human antigen-specific regulatory CD4+ T cells that require antigen-specific activation for suppression.J Immunol. 2003 Dec 15;171(12):6431-41. doi: 10.4049/jimmunol.171.12.6431. J Immunol. 2003. PMID: 14662842
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Oncoimmunology. 2013 May 1;2(5):e24238. doi: 10.4161/onci.24238. Oncoimmunology. 2013. PMID: 23762803 Free PMC article.
-
Effect of interleukin-2 treatment combined with magnetic fluid hyperthermia on Lewis lung cancer-bearing mice.Biomed Rep. 2016 Jan;4(1):59-62. doi: 10.3892/br.2015.540. Epub 2015 Nov 5. Biomed Rep. 2016. PMID: 26870335 Free PMC article.
-
Trial Watch:: Oncolytic viruses for cancer therapy.Oncoimmunology. 2014 Jun 1;3:e28694. doi: 10.4161/onci.28694. eCollection 2014. Oncoimmunology. 2014. PMID: 25097804 Free PMC article. Review.
-
Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone.Cancer Immunol Immunother. 2019 Sep;68(9):1417-1428. doi: 10.1007/s00262-019-02377-x. Epub 2019 Aug 17. Cancer Immunol Immunother. 2019. PMID: 31422446 Free PMC article.
-
Molecular networks of FOXP family: dual biologic functions, interplay with other molecules and clinical implications in cancer progression.Mol Cancer. 2019 Dec 9;18(1):180. doi: 10.1186/s12943-019-1110-3. Mol Cancer. 2019. PMID: 31815635 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
